Low- versus high-dose rituximab for antibody-mediated rejection after kidney transplantation

The treatment of antibody-mediated rejection (AMR) after kidney transplantation is based on the association of

plasma exchange (PE) with or without rituximab, with or without intravenous immunoglobulins (Iv-Ig). However, if used, the optimal dose of rituximab is still unknown. Furthermore, an increased risk of infection has been reported in kidney-transplant patients receiving rituximab, mainly when combined with polyclonal antibodies. Here, we compared the efficacy and safety of low-dose (375 mg/m²/week for 2 weeks) to high-dose (375 mg/m²/ week for 3–5 weeks, median 4) rituximab given for AMR after kidney transplantation (read more).
Print this post